{"id":1874,"date":"2025-10-22T10:40:05","date_gmt":"2025-10-22T08:40:05","guid":{"rendered":"https:\/\/okuvision.de\/therapy-treatment\/"},"modified":"2026-05-21T13:47:56","modified_gmt":"2026-05-21T11:47:56","slug":"retinitis-pigmentosa-treatment","status":"publish","type":"page","link":"https:\/\/okuvision.de\/en\/retinitis-pigmentosa-treatment\/","title":{"rendered":"Therapy & Treatment"},"content":{"rendered":"

[vc_row unlock_row_content=”yes” row_height_percent=”0″ override_padding=”yes” h_padding=”0″ top_padding=”0″ bottom_padding=”0″ back_color=”color-206913″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″ content_parallax=”0″ uncode_shortcode_id=”126459″ back_color_type=”uncode-palette”][vc_column width=”1\/1″]\n

\n \n \n
<\/div>\n
<\/div>\n \n \n
\n \n
\n
\n \n \n

\n Retinitis pigmentosa: Overview of treatment options <\/h1>\n \n
\n
\n

What options are available \u2013 realistic goals, the role of TES therapy (OkuStim\u00ae), and how it differs from gene and rehabilitation approaches.<\/p>\n <\/div>\n \n <\/div>\n \n \n <\/div>\n \n \n

\n \"Okuvision <\/div>\n <\/div>\n \n <\/div>\n \n<\/div>\n\n\n[\/vc_column][\/vc_row][vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”0″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″ content_parallax=”0″ uncode_shortcode_id=”176312″][vc_column width=”1\/1″][vc_row_inner][vc_column_inner width=”2\/3″][vc_custom_heading text_font=”font-714446″ text_size=”fontsize-914237″ text_weight=”300″ uncode_shortcode_id=”482476″]Therapy goals: What can realistically be achieved[\/vc_custom_heading][\/vc_column_inner][vc_column_inner column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_visibility=”yes” medium_width=”0″ mobile_visibility=”yes” mobile_width=”0″ width=”1\/3″ uncode_shortcode_id=”542260″][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_visibility=”yes” medium_width=”0″ mobile_visibility=”yes” mobile_width=”0″ width=”1\/3″ uncode_shortcode_id=”163215″][\/vc_column_inner][vc_column_inner width=”2\/3″][vc_column_text uncode_shortcode_id=”206887″]Retinitis pigmentosa (RP) cannot currently be cured. The scientific literature recommends aligning therapy and care with three goals:
\n(1) slowing functional decline
\n(2) treating complications (e.g., lens opacification, macular oedema) in line with guidelines, and
\n(3) maintaining quality of life through rehabilitation and assistive devices. These goals reflect the current evidence and care landscape.1<\/sup>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″ content_parallax=”0″ uncode_shortcode_id=”137928″][vc_column width=”1\/1″][vc_row_inner][vc_column_inner width=”2\/3″][vc_custom_heading text_font=”font-714446″ text_size=”fontsize-914237″ text_weight=”300″ uncode_shortcode_id=”971846″]Diagnostics first: Who benefits from which option?[\/vc_custom_heading][\/vc_column_inner][vc_column_inner column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_visibility=”yes” medium_width=”0″ mobile_visibility=”yes” mobile_width=”0″ width=”1\/3″ uncode_shortcode_id=”542260″][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_visibility=”yes” medium_width=”0″ mobile_visibility=”yes” mobile_width=”0″ width=”1\/3″ uncode_shortcode_id=”163215″][\/vc_column_inner][vc_column_inner width=”2\/3″][vc_column_text uncode_shortcode_id=”153563″]RP is hereditary and genetically highly diverse. Genetic testing can set the course for therapy (e.g., assessing gene therapy for certain mutations), supports counselling, and facilitates access to studies. At the same time, only a small proportion of those affected currently have an approved gene therapy option (e.g., RPE65-associated forms).1<\/sup> <\/p>\n

Important for follow-up monitoring:<\/strong> In RP, the visual field area typically decreases exponentially; studies report average annual declines (AAD) of around ~5\u201317%\u2014depending, among other factors, on the measurement method and baseline level. Measurements should therefore be repeated in as standardised a way as possible (same method, similar conditions).[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″ content_parallax=”0″ uncode_shortcode_id=”103130″][vc_column width=”1\/1″][vc_custom_heading text_font=”font-714446″ text_size=”fontsize-914237″ text_weight=”300″ uncode_shortcode_id=”173997″]TES (OkuStim\u00ae) in studies \u2013 explained briefly[\/vc_custom_heading][vc_row_inner][vc_column_inner column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_visibility=”yes” medium_width=”0″ mobile_visibility=”yes” mobile_width=”0″ width=”1\/3″ uncode_shortcode_id=”184318″][\/vc_column_inner][vc_column_inner width=”2\/3″][vc_column_text text_lead=”yes” uncode_shortcode_id=”887171″]What is TES? Transcorneal electrical stimulation (TES) stimulates the retina via weak alternating currents at the surface of the eye. The aim is to activate cellular protective mechanisms to preserve existing visual function for longer.[\/vc_column_text][vc_custom_heading heading_semantic=”h3″ text_size=”h3″ uncode_shortcode_id=”197836″]What does the clinical evidence show?[\/vc_custom_heading][vc_column_text uncode_shortcode_id=”134063″]A 12-month interventional randomised analysis with monocular application (weekly, 30 min) showed: visual field area (VFA) loss was lower in the treated eye than in the fellow or sham eye; a dose\u2013response relationship was also observed (higher current intensity \u2192 greater effect). Tolerability: the published analyses predominantly described mild, transient complaints (e.g., dry eyes); severe therapy-related events were not typical, and no current-intensity-dependent increase in severe events was observed.3<\/sup>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”2″ bottom_padding=”3″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″ content_parallax=”0″ cvc_pattern_bottom_left=”pattern” uncode_shortcode_id=”193115″][vc_column column_width_percent=”100″ align_horizontal=”align_center” gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_width=”0″ mobile_width=”0″ width=”1\/1″ uncode_shortcode_id=”153108″][vc_single_image media=”2947″ media_width_percent=”100″ uncode_shortcode_id=”103588″][vc_column_text uncode_shortcode_id=”139692″]CONCLUSION:<\/strong> TES does not cure RP, but studies suggest it can slow visual field loss. Whether TES is suitable for you should be clarified with your ophthalmologist\u2014including goals, appropriate current intensity, and standardised follow-up checks.2,3<\/sup>[\/vc_column_text][\/vc_column][\/vc_row][vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”0″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″ content_parallax=”0″ uncode_shortcode_id=”100668″][vc_column width=”1\/1″][vc_row_inner][vc_column_inner width=”2\/3″][vc_custom_heading text_font=”font-714446″ text_size=”fontsize-914237″ text_weight=”300″ uncode_shortcode_id=”829882″]Distinction: Other therapeutic directions in research[\/vc_custom_heading][\/vc_column_inner][vc_column_inner column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_visibility=”yes” medium_width=”0″ mobile_visibility=”yes” mobile_width=”0″ width=”1\/3″ uncode_shortcode_id=”542260″][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_visibility=”yes” medium_width=”0″ mobile_visibility=”yes” mobile_width=”0″ width=”1\/3″ uncode_shortcode_id=”163215″][\/vc_column_inner][vc_column_inner width=”2\/3″][vc_custom_heading heading_semantic=”h3″ text_size=”h3″ uncode_shortcode_id=”129666″]Gene therapy (e.g., RPE65) \u2013 who is it suitable for?[\/vc_custom_heading][vc_column_text uncode_shortcode_id=”135938″]Gene therapy is available for a small subgroup with RPE65 mutations; for the majority of RP forms, there is still no approved option. Clinical studies are crucial here to evaluate the efficacy and safety of new approaches.1 <\/sup>[\/vc_column_text][vc_custom_heading heading_semantic=”h3″ text_size=”h3″ uncode_shortcode_id=”187992″]Optogenetics, cell replacement, implants \u2013 what is in studies?[\/vc_custom_heading][vc_column_text uncode_shortcode_id=”143716″]Optogenetic approaches, cell-based therapies and retinal implants are being investigated scientifically. They are intended to reactivate or supplement retinal function\u2014so far predominantly in the context of studies with strict indication criteria.4 <\/sup>[\/vc_column_text][vc_custom_heading heading_semantic=”h3″ text_size=”h3″ uncode_shortcode_id=”162587″]Treatment of comorbidities & rehabilitation[\/vc_custom_heading][vc_column_text uncode_shortcode_id=”189200″]Regardless of disease-specific therapies, comorbidities (e.g., cataract, macular oedema) should be treated in line with guidelines. At the same time, low-vision rehabilitation is central to maintaining mobility, ability to work and participation. Studies describe a substantial burden in everyday life (psychosocial, occupational, economic)\u2014rehabilitation, assistive devices and counselling are therefore beneficial early on.1<\/sup>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″ content_parallax=”0″ uncode_shortcode_id=”137928″][vc_column width=”1\/1″][vc_row_inner][vc_column_inner width=”2\/3″][vc_custom_heading text_font=”font-714446″ text_size=”fontsize-914237″ text_weight=”300″ uncode_shortcode_id=”270723″]What does this mean in practical terms for those affected?[\/vc_custom_heading][\/vc_column_inner][vc_column_inner column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_visibility=”yes” medium_width=”0″ mobile_visibility=”yes” mobile_width=”0″ width=”1\/3″ uncode_shortcode_id=”542260″][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_visibility=”yes” medium_width=”0″ mobile_visibility=”yes” mobile_width=”0″ width=”1\/3″ uncode_shortcode_id=”163215″][\/vc_column_inner][vc_column_inner width=”2\/3″][vc_column_text uncode_shortcode_id=”179164″]<\/p>\n

    \n
  • Set goals: Do you want to preserve function, make everyday life easier, or both? Discuss priorities openly.1<\/sup> <\/li>\n
  • Consider TES: If retinal function is preserved, TES (e.g., with OkuStim\u00ae) may be an option\u2014bearing in mind the dose-dependent slowing of VFA loss and favourable tolerability in studies.2,3<\/sup><\/li>\n
  • Gene therapy selectively: Review genetic findings (e.g., RPE65). For many other forms, studies are currently the bridge to new therapies.1,4<\/sup> <\/li>\n
  • Take a holistic approach: Rehabilitation & assistive devices (contrast\/lighting, magnification, orientation\/mobility, digital assistance) are an integral part of care and can noticeably stabilise quality of life.1<\/sup><\/li>\n<\/ul>\n

    [\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″ content_parallax=”0″ uncode_shortcode_id=”609480″][vc_column width=”1\/1″][vc_separator uncode_shortcode_id=”100849″ sep_color_type=”uncode-solid” sep_color_solid=”#cddfed”][vc_custom_heading heading_semantic=”h6″ text_size=”h4″ uncode_shortcode_id=”493566″]References[\/vc_custom_heading][vc_column_text text_lead=”small” uncode_shortcode_id=”149335″]1 Cross N et al. Retinitis Pigmentosa: Burden of Disease and Current Unmet Needs. Clin Ophthalmol. 2022;16:1993\u20132010. <\/p>\n

    2 Stett A et al. Transcorneal electrical stimulation dose-dependently slows the visual field loss in RP. Transl Vis Sci Technol. 2023;12(2):29. <\/p>\n

    3 Jolly JK et al. Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa: A Multicenter Safety Study (TESOLA). Ophthalmic Res. 2020;63(3):234\u2013243. <\/p>\n

    4 McClements ME et al. Optogenetic Gene Therapy for the Degenerate Retina: Recent Advances. Front Neurosci. 2020;14. <\/p>\n

    5 Allen PJ. Retinal prostheses: Where to from here? Clin Exp Ophthalmol. 2021;49:418\u2013429.[\/vc_column_text][\/vc_column][\/vc_row][vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ back_color=”color-206913″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″ content_parallax=”0″ uncode_shortcode_id=”118356″ back_color_type=”uncode-palette”][vc_column column_width_percent=”100″ align_horizontal=”align_center” gutter_size=”4″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_width=”0″ mobile_width=”0″ width=”1\/1″ uncode_shortcode_id=”152446″][vc_custom_heading text_font=”font-714446″ text_size=”fontsize-914237″ text_weight=”300″ uncode_shortcode_id=”109998″]Insights into Therapy,
    \nResearch & Company[\/vc_custom_heading][vc_row_inner][vc_column_inner width=”1\/1″][uncode_index el_id=”index-974899″ index_type=”carousel” loop=”size:3|order_by:date|post_type:post|categories:110|taxonomy_count:10″ carousel_lg=”3″ carousel_md=”2″ carousel_sm=”1″ thumb_size=”sixteen-nine” gutter_size=”3″ post_items=”media|featured|onpost|original,date,title|-,text|excerpt|200,category|colorbg|relative|display-icon” carousel_height=”equal” carousel_interval=”3000″ carousel_navspeed=”400″ advanced_nav=”yes” el_id1=”index-974899″ stage_padding=”0″ single_back_color=”color-942029″ single_overlay_opacity=”50″ single_padding=”2″ single_title_dimension=”h4″ single_border=”yes” uncode_shortcode_id=”186887″][uncode_carousel_nav padding=”0″ h_align=”center” hide_arrows=”yes” dots_style=”lines” hide_counter=”yes” uncode_shortcode_id=”207978″ target=”index-974899″ dot_single_width=”12″ dot_single_active=”24″ dot_single_height=”12″ dot_single_radius=”999″][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

    [vc_row unlock_row_content=”yes” row_height_percent=”0″ override_padding=”yes” h_padding=”0″ top_padding=”0″ bottom_padding=”0″ back_color=”color-206913″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″ content_parallax=”0″ uncode_shortcode_id=”126459″ back_color_type=”uncode-palette”][vc_column width=”1\/1″][\/vc_column][\/vc_row][vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1874","page","type-page","status-publish","hentry"],"yoast_head":"\nRetinitis pigmentosa: Treatment options & evidence<\/title>\n<meta name=\"description\" content=\"RP therapy explained: goals, options, evidence on TES (OkuStim\u00ae), distinction from gene therapy & rehabilitation. Next steps for those affected.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/okuvision.de\/en\/retinitis-pigmentosa-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Therapy & Treatment\" \/>\n<meta property=\"og:description\" content=\"RP therapy explained: goals, options, evidence on TES (OkuStim\u00ae), distinction from gene therapy & rehabilitation. Next steps for those affected.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/okuvision.de\/en\/retinitis-pigmentosa-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Okuvision\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-21T11:47:56+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/okuvision.de\\\/en\\\/retinitis-pigmentosa-treatment\\\/\",\"url\":\"https:\\\/\\\/okuvision.de\\\/en\\\/retinitis-pigmentosa-treatment\\\/\",\"name\":\"Retinitis pigmentosa: Treatment options & evidence\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/okuvision.de\\\/en\\\/#website\"},\"datePublished\":\"2025-10-22T08:40:05+00:00\",\"dateModified\":\"2026-05-21T11:47:56+00:00\",\"description\":\"RP therapy explained: goals, options, evidence on TES (OkuStim\u00ae), distinction from gene therapy & rehabilitation. Next steps for those affected.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/okuvision.de\\\/en\\\/retinitis-pigmentosa-treatment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/okuvision.de\\\/en\\\/retinitis-pigmentosa-treatment\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/okuvision.de\\\/en\\\/retinitis-pigmentosa-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/okuvision.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Therapy & Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/okuvision.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/okuvision.de\\\/en\\\/\",\"name\":\"Okuvision\",\"description\":\"\u2013 Sehen erhalten\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/okuvision.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Retinitis pigmentosa: Treatment options & evidence","description":"RP therapy explained: goals, options, evidence on TES (OkuStim\u00ae), distinction from gene therapy & rehabilitation. Next steps for those affected.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/okuvision.de\/en\/retinitis-pigmentosa-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Therapy & Treatment","og_description":"RP therapy explained: goals, options, evidence on TES (OkuStim\u00ae), distinction from gene therapy & rehabilitation. Next steps for those affected.","og_url":"https:\/\/okuvision.de\/en\/retinitis-pigmentosa-treatment\/","og_site_name":"Okuvision","article_modified_time":"2026-05-21T11:47:56+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/okuvision.de\/en\/retinitis-pigmentosa-treatment\/","url":"https:\/\/okuvision.de\/en\/retinitis-pigmentosa-treatment\/","name":"Retinitis pigmentosa: Treatment options & evidence","isPartOf":{"@id":"https:\/\/okuvision.de\/en\/#website"},"datePublished":"2025-10-22T08:40:05+00:00","dateModified":"2026-05-21T11:47:56+00:00","description":"RP therapy explained: goals, options, evidence on TES (OkuStim\u00ae), distinction from gene therapy & rehabilitation. Next steps for those affected.","breadcrumb":{"@id":"https:\/\/okuvision.de\/en\/retinitis-pigmentosa-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/okuvision.de\/en\/retinitis-pigmentosa-treatment\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/okuvision.de\/en\/retinitis-pigmentosa-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/okuvision.de\/en\/"},{"@type":"ListItem","position":2,"name":"Therapy & Treatment"}]},{"@type":"WebSite","@id":"https:\/\/okuvision.de\/en\/#website","url":"https:\/\/okuvision.de\/en\/","name":"Okuvision","description":"\u2013 Sehen erhalten","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/okuvision.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/okuvision.de\/en\/wp-json\/wp\/v2\/pages\/1874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/okuvision.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/okuvision.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/okuvision.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/okuvision.de\/en\/wp-json\/wp\/v2\/comments?post=1874"}],"version-history":[{"count":20,"href":"https:\/\/okuvision.de\/en\/wp-json\/wp\/v2\/pages\/1874\/revisions"}],"predecessor-version":[{"id":2966,"href":"https:\/\/okuvision.de\/en\/wp-json\/wp\/v2\/pages\/1874\/revisions\/2966"}],"wp:attachment":[{"href":"https:\/\/okuvision.de\/en\/wp-json\/wp\/v2\/media?parent=1874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}